Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Articles

Older adults from Hispanic, Asian, and non-Hispanic Black populations in the US are more likely to reach age 100 compared with their non-Hispanic White peers.

Who Lives to 100? New Research Reveals Differences Across Racial, Ethnic Groups

Cameron Santoro is an associate editor for 

), AJMC.com, and The Center for Biosimilars

Panelists proposed policy solutions to ensure long-term sustainability of infused biosimilars amid current challenges, including average sales price erosion and reimbursement issues.

Policy Proposals Aim to Stimulate the Long-Term Sustainability of Infused Biosimilars

Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.

She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on 

Videos

Divya Gupta, MD, assistant professor at the Northwestern University Feinberg School of Medicine, emphasized the transformative role of biomarker-driven therapies in advancing non–small cell lung cancer (NSCLC) treatment and highlighted the critical importance of multidisciplinary collaboration.

Optimizing Outcomes in NSCLC With Precision Medicine and Teamwork

Insurance hurdles worsen delays, force abandoned treatments, and result in hospitalizations and deaths, radiation oncologists report nationwide.

Prior Authorization Delays Cause Serious Harm to Patients With Cancer 

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Multidisciplinary Approaches to Paraneoplastic LEMS: Insights for Healthcare Decision-Makers 

LEMS and SCLC: Unraveling the Neuromuscular-Cancer Connection

Video content above is prompted by the following:

What is Lambert-Eaton myasthenic syndrome (LEMS), and what is the connection between LEMS and small cell lung cancer (SCLC)?

How does LEMS in patients with SCLC differ from other neuromuscular disorders that may be on the differential, such as myasthenia gravis?

What are the long-term effects of LEMS on physical and mental health, and how do they vary across different patient populations?

How does the dual diagnosis of SCLC and LEMS affect the trajectory of cancer care for patients?

A medical expert discusses the key aspects of Lambert-Eaton Myasthenic Syndrome (LEMS) in the context of small cell lung cancer (SCLC), including its differential diagnosis, long-term effects, economic burden, and how a multidisciplinary approach can optimize patient care and reduce health care 

A medical expert discusses how Lambert-Eaton myasthenic syndrome is closely linked to small cell lung cancer, the challenges in differentiating it from other neuromuscular disorders like myasthenia gravis, and the impact of dual diagnosis on cancer care and patient outcomes.

A medical expert discusses strategies that have successfully mitigated the economic impact of LEMS on patients and health care systems, and how a multidisciplinary approach can reduce the clinical and economic burden of LEMS on health care delivery.

Strategies to Alleviate the Clinical and Economic Burden of LEMS

A medical expert discusses how disparities in health care access affect the management and outcomes of Lambert-Eaton myasthenic syndrome (LEMS) in patients with small cell lung cancer, how health care providers can quantify the economic burden of LEMS on both patients and health care systems, the role of patient-reported outcomes in providing deeper insights into the clinical and economic burden of LEMS, and how health systems can utilize real-world data to better understand the indirect costs of LEMS.

The Clinical and Economic Impact of LEMS in SCLC Care

Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder often associated with small cell lung cancer (SCLC), characterized by muscle weakness and autonomic dysfunction. Unlike myasthenia gravis, LEMS involves presynaptic calcium channel antibodies, leading to impaired neuromuscular transmission. The presence of SCLC significantly impacts the management and prognosis of LEMS, necessitating a comprehensive approach to cancer care. Long-term effects of LEMS include persistent physical and mental health challenges, with variability across patient populations. The dual diagnosis of SCLC and LEMS complicates treatment strategies and influences patient outcomes.

LEMS and SCLC: Unraveling the Neuromuscular-Cancer Connection

EP: 1.LEMS and SCLC: Unraveling the Neuromuscular-Cancer Connection

EP: 2.Strategies to Alleviate the Clinical and Economic Burden of LEMS

EP: 3.The Clinical and Economic Impact of LEMS in SCLC Care